+91 9620349000, +91 7090001946 
enquiry@adityaedu.net 
As part of the 74th Indian Pharmaceutical Congress (IPC), Aditya Bangalore Institute of Pharmacy Education and Research (ABIPER) successfully organized a three-day national-level academic conference on “AI-Powered Drug Discovery” from 19th to 21st December 2025 at the Bangalore International Exhibition Centre (BIEC), Bengaluru.
The conference aimed to expose students, researchers, academicians, and industry professionals to the rapid advancements in artificial intelligence and its applications across the drug discovery and pharmaceutical research lifecycle, while strengthening collaboration between industry and academia.
Day 1 – December 19, 2025
The first day of the conference was chaired by Dr. M. D. Dhanaraju, Dean, School of Pharmacy, Godavari Global University (GGU). The Chairperson formally invited the speakers and guided the day’s proceedings.
- Dr. Achintya Das, Head – Digital Transformation and Modeling, Syngene International, delivered a session on the current status and challenges of AI in drug discovery, highlighting real-world industrial perspectives.
- Dr. Raghu R., CEO, Molecular Solutions, spoke on AI-powered drug discovery technologies for Pharma R&D, emphasizing next-generation computational platforms.
- Dr. Jitesh Doshi, Senior Research Scientist, Peptris Technologies Pvt. Ltd., explained AI-based approaches to predict activity from binding poses in early-stage drug discovery.
- Dr. Viswanadhan, Vice President, Molecular Solutions, presented insights on AI-accelerated hit identification and virtual screening.
- Dr. Santosh Kumar N. Patil, Director, Syngene International Limited, and Dr. R. Muruganantham, Senior Principal Investigator, Syngene International Limited, jointly discussed the medicinal chemist’s perspective on AI, its opportunities, challenges, and future direction.
After each session, participants actively interacted with the speakers through question-and-answer discussions, which enriched the learning experience. The speakers were felicitated by the Chairperson at the end of the sessions. The day concluded with a closing session by Dr. Sowjanya Battu, Vice Principal, ABIPER.
Day 2 – December 20, 2025
The second day was chaired by Dr. V. Kusum Devi, Principal, NITTE College of Pharmaceutical Sciences, who invited the speakers and facilitated the sessions.
- Dr. Raja, Founder & CEO, Genotypic Technology, delivered a session on AI-driven genomics and its role in modern drug discovery.
- Mr. Anbu Dinesh Jayakumar, Applications Scientist, Molecular Solutions, conducted sessions on AI-powered retrosynthesis, process chemistry, impurity prediction, and high-throughput screening, including live demonstrations.
- Dr. Ravi, Chief Scientific Officer, Pharm DEM, spoke on AI-powered formulation intelligence to accelerate pharmaceutical R&D.
- Dr. Viswanath, Principal Scientist – DMPK, Jubilant Biosys, discussed the role of AI and ML in drug metabolism and pharmacokinetics.
- Dr. Sooriya Kumar, Associate Director, Jubilant Biosys, presented on reinforcement learning-based molecular generation in drug discovery.
- Dr. Jagadish, Vice President, Pharmaids, emphasized the importance of domain expertise in preventing errors in AI-driven drug discovery.
- Mr. Kamaraj, CSO, TransGene IT Solutions, highlighted why electronic lab notebooks are essential for AI-ready research environments.
The day also featured a Career Opportunities in Pharma panel discussion, offering guidance on emerging roles and required skill sets. After interactive Q&A sessions, the speakers were felicitated by the Chairperson, followed by the closing remarks by Dr. Sowjanya Battu, Vice Principal, ABIPER.
Day 3 – December 21, 2025
The final day of the conference was chaired by Dr. Raghu R., CEO, Molecular Solutions, who invited the speakers and moderated the sessions.
- Dr. V. N. Balaji, Drug Discovery Research Advisor, delivered a session on AI-powered JNK1 hit prediction using advanced descriptors for improved classification and regression.
- Ms. Nandhini Balan, Regulatory Affairs Associate, AstraZeneca, presented a session on CTIS and digital innovations shaping the future of clinical trial submissions.
Participants actively engaged with the speakers through interactive discussions and question-and-answer sessions. The speakers were felicitated by the Chairperson at the conclusion of the sessions. The conference concluded with a closing session by Dr. Sowjanya Battu, Vice Principal, ABIPER, who thanked the Chairpersons, speakers, participants, and organizing team.
Conclusion
The three-day conference on “AI-Powered Drug Discovery”, conducted by ABIPER during the 74th Indian Pharmaceutical Congress, was highly informative and impactful. The program provided participants with comprehensive insights into how artificial intelligence is transforming pharmaceutical research, while reaffirming the importance of scientific expertise and ethical responsibility.
The event successfully highlighted ABIPER’s commitment to academic excellence, research innovation, and industry engagement, making it a significant academic contribution during the 74th IPC.
